Si-HPMC-encapsulated insulin-producing cells for the treatment of type 1 diabetes

Patent metadata

Field	Value
Publication number	US-10632154-B2
Application number	US-201615773659-A
Country	US
Kind code	B2
Filing date	Nov 10, 2016
Priority date	Nov 10, 2015
Publication date	Apr 28, 2020
Grant date	Apr 28, 2020

Abstract

The present invention relates to the use of insulin-producing cells encapsulated in silanized hydroxypropyl methylcellulose (Si-HPMC) for the treatment of type 1 diabetes. Methods and kits are also provided for restoring and/or maintaining euglycemia in type 1 diabetic patients and in type 1 prediabetic patients.

First claim

What is claimed is:

1. A method for treating type 1 diabetes in a patient, in particular for restoring and/or maintaining euglycemia in a type 1 diabetic patient or a type 1 prediabetic patient, said method comprising a step of administering to said patient a therapeutically effective amount of Si-HPMC-encapsulated insulin-producing cells, wherein the insulin-producing cells are macro-encapsulated in Si-HPMC flat-sheet membranes or in Si-HPMC hollow fiber membranes or wherein the insulin-producing cells are micro-encapsulated.

2. The method according to claim 1 , wherein Si-HPMC has the following simplified formula:
(HPMC)—O—CH 2 —CH(OH)—CH 2 —O—(CH 3 ) 3 —Si(O − Na + ) 3   (I).

3. The method according to claim 1 , wherein the insulin-producing cells are isolated allogenic pancreatic islets or isolated xenogenic pancreatic islets.

4. The method according to claim 1 , wherein the insulin-producing cells are isolated cells selected from the group consisting of pancreatic β-cells, pancreatic β-like cells, and any combination thereof.

5. The method according to claim 4 , wherein pancreatic β-like cells are obtained by differentiation of embryonic stem cells, induced pluripotent stem cells, multipotent mesenchymal stromal cells, ductal cells, hepatocytes, or β-cells.

6. The method according to claim 1 , wherein the insulin-producing cells are micro-encapsulated into Si-HPMC microbeads, Si-HPMC microspheres, or Si-HPMC microcapsules.

7. The method according to claim 1 , wherein the insulin-producing cells are encapsulated in Si-HPMC with at least one therapeutic compound.

8. The method according to claim 1 , wherein the type 1 diabetes patient suffers from brittle diabetes.

9. The method according to claim 1 , wherein the Si-HPMC-encapsulated insulin-producing cells are administered by subcutaneous injection, by intramuscular injection, or by implantation in the peritoneal cavity, in the mesentery, in the omemtum, or in the renal capsule.

Assignees

• Ecole Nat Veterinaire
• Chu Nantes
• Univ Nantes
• Inst Nat Sante Rech Med
• Institute National De La Sante Et De La Rech Medicale

Inventors

• Bach Jean-Marie
• Mosser Mathilde
• Salama Apolline
• Moure Anne
• Leveque Xavier
• Weiss Pierre
• Guicheux Jérôme
• Boyer Cécile
• Riochet David

Classifications

• A61K9/1652

  Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623) · CPC title

• A61K9/5047

  Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• C12N2533/30

  Synthetic polymers · CPC title